Skip to main content
Hit enter to search or ESC to close
Close Search
Hepion PharmaceuticalsHepion Pharmaceuticals
Menu
  • About
    • Leadership
    • Board of Directors
  • Portfolio
    • Hepatocellular Carcinoma
    • Gravitas Life Sciences
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    Hepion Pharmaceuticals
    Category

    Videos

    Edmonton-based Hepion Developing Novel Liver Drug [Global News] Media PlacementsVideos

    Edmonton-based Hepion Developing Novel Liver Drug [Global News]

    Admin
    AdminJune 23, 2023
    Media PlacementsVideos

    Hepion Pharmaceuticals 2023 NASDAQ Closing Bell

    Admin
    AdminFebruary 20, 2023
    Media PlacementsVideos

    Hepion Pharmaceuticals CEO Robert Foster – Dash To Beat NASH (via Seeking Alpha)

    Admin
    AdminFebruary 17, 2022
    Media PlacementsVideos

    Treating Chronic Liver Disease – Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster [via Seeking Alpha]

    Admin
    AdminMay 26, 2021
    Industry NewsVideos

    Voclosporin Success Story [via Applied Pharmaceutical Innovation]

    Admin
    AdminFebruary 10, 2021
    Media PlacementsVideos

    Hepion Tackles NASH in P2 with Cyclophilin Inhibitor [Breaking Biotech]

    Admin
    AdminOctober 11, 2020
    Media PlacementsVideos

    Rencofilstat (CRV431) Mechanism of Action [Video]

    Admin
    AdminJanuary 30, 2020
    Media PlacementsVideos

    Introduction to Hepion Pharmaceuticals

    Admin
    AdminAugust 2, 2019
    About
    Newsroom
    Investors
    Contact
    Subscribe for Updates

    © 2026 Hepion Pharmaceuticals | Disclaimer & Terms of Use

    Close Menu
    • About
      • Leadership
      • Board of Directors
    • Portfolio
      • Hepatocellular Carcinoma
      • Gravitas Life Sciences
    • Newsroom
    • Investors
      • Investor Overview
      • Press Releases
      • Presentations
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact